R. James White, MD, PhD

Dr. White is a Professor of Medicine in pulmonary diseases and critical care, pediatrics, and pharmacology & physiology at the University of Rochester Medical Center in Rochester, NY, and Director of the University of Rochester’s pulmonary arterial hypertension (PAH) program. His research focuses on understanding the vascular biology of PAH, and providing better care to patients with a rare disease of the lung blood vessels and PAH. He has participated in major clinical trials for PAH medications, including tadalafil, treprostinil, bardoxolone and for rituxan in scleroderma-associated PAH, and provides leadership and development advice to biopharma companies including PhaseBio, United Therapeutics, Reata Pharmaceuticals, Gilead, Bayer and Celtaxsys. Dr. White earned his MD and PhD from the University of Pittsburgh School of Medicine. He completed an internal medicine residency and a fellowship in pulmonary/critical care at the University of Rochester Medical Center.